Celecoxib concentration predicts decrease in prostaglandin E2concentrations in nipple aspirate fluid from high risk women

Table 2 Median concentrations of PGE2 in NAF and celecoxib in plasma in ng/ml based on celecoxib dose¹

Population: Dose		Before (N)	After (N)	After v.	P value
		Treatment	Treatment	Before(N)²	ΔPGE2	Celecoxib Level & ΔPGE₂
200 mg twice daily
Overall	PGE2	13.75(19)	17.78(19)	0.37(19)	0.54	0.29
	Celecoxib		223.7(19)
Premenopausal	PGE2	13.75(5)	21.85(5)	5.50(5)	0.63
	Celecoxib		117.6(5)
Postmenopausal	PGE2	14.15(14)	13.79(14)	-0.34(14)	0.86
	Celecoxib		267.5(14)
400 mg twice daily
Overall	PGE2	13.80(22)	13.22(22)	-1.72(22)	0.83	0.006
	Celecoxib		759.8(22)
Premenopausal	PGE2	15.7(11)	36.1(11)	7.31(11)	0.17
	Celecoxib		227.3(11)
Postmenopausal	PGE2	8.33(11)³	6.81(11)	-4.95(11)	0.03
	Celecoxib		860.6(11)

1: N: sample size; NAF: nipple aspirate fluid. P values assess ΔPGE₂ (was the change from before to after treatment significant) and celecoxib level & ΔPGE₂ (was the celecoxib level after treatment related to the change in PGE₂)
2: Median change in PGE₂ levels after treatment.
3: Only matched samples are included in this analysis, unlike the previous report which included PGE2 values for all subjects [16].

ISSN: 1471-2407